PMID: 9419378Feb 21, 1998Paper

Gsalpha-selective G protein antagonists

Proceedings of the National Academy of Sciences of the United States of America
M HoheneggerM Freissmuth

Abstract

Suramin acts as a G protein inhibitor because it inhibits the rate-limiting step in activation of the Galpha subunit, i.e., the exchange of GDP for GTP. Here, we have searched for analogues that are selective for Gsalpha. Two compounds have been identified: NF449 (4,4',4",4'"-[carbonyl-bis[imino-5,1,3-benzenetriyl bis-(carbonylimino)]]tetrakis-(benzene-1,3-disulfonate) and NF503 (4, 4'-[carbonylbis[imino-3,1-phenylene-(2, 5-benzimidazolylene)carbonylimino]]bis-benzenesulfonate). These compounds (i) suppress the association rate of guanosine 5'-[gamma-thio]triphosphate ([35S]GTP[gammaS]) binding to Gsalpha-s but not to Gialpha-1, (ii) inhibit stimulation of adenylyl cyclase activity in S49 cyc- membranes (deficient in endogenous Gsalpha) by exogenously added Gsalpha-s, and (iii) block the coupling of beta-adrenergic receptors to Gs with half-maximum effects in the low micromolar range. In contrast to suramin, which is not selective, NF503 and NF449 disrupt the interaction of the A1-adenosine receptor with its cognate G proteins (Gi/Go) at concentrations that are >30-fold higher than those required for uncoupling of beta-adrenergic receptor/Gs tandems; similarly, the angiotensin II type-1 receptor (a prototypical Gq-coupled recep...Continue Reading

References

Oct 1, 1992·Trends in Pharmacological Sciences·W Schütz, M Freissmuth
Oct 1, 1992·Trends in Biochemical Sciences·J R Hepler, A G Gilman
Jan 1, 1991·Annual Review of Biochemistry·H G DohlmanR J Lefkowitz
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M FreissmuthA D Strosberg
May 10, 1991·Science·M I SimonN Gautam
May 7, 1990·Biochimica Et Biophysica Acta·L BirnbaumerA M Brown
Jan 1, 1986·Journal of Cardiovascular Pharmacology·M FreissmuthW Schütz
Sep 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·M FreissmuthW Schütz
Oct 1, 1994·Naunyn-Schmiedeberg's Archives of Pharmacology·S Offermanns, G Schultz
Jan 1, 1994·Methods in Enzymology·S M Mumby, M E Linder
Jul 1, 1994·Naunyn-Schmiedeberg's Archives of Pharmacology·S FreundM J Lohse
Sep 8, 1994·Nature·D E Clapham
Aug 1, 1993·Trends in Pharmacological Sciences·R J LefkowitzT Costa
Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·K L LaugwitzG Schultz
Jan 5, 1996·Biochemical and Biophysical Research Communications·T ShibataH Miyazaki
Jan 1, 1996·Annual Review of Pharmacology and Toxicology·T GudermannG Schultz
Nov 15, 1996·Journal of Chromatography. B, Biomedical Applications·M Kassack, P Nickel
Jan 1, 1997·Annual Review of Biochemistry·S R Sprang

❮ Previous
Next ❯

Citations

Feb 19, 2000·Biochemical and Biophysical Research Communications·D SlivaD English
Jun 2, 2000·Biochemical and Biophysical Research Communications·G BoguslawskiD English
Mar 5, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anders A Jensen, Tracy A Spalding
Jan 15, 2014·Neuropeptides·Hou DiandongLiang Zaifu
Apr 6, 2013·Trends in Pharmacological Sciences·Alan V Smrcka
Jun 6, 2003·European Journal of Pharmacology·Martin HülsmannFritz Markwardt
Jun 15, 1999·Trends in Pharmacological Sciences·M FreissmuthC Nanoff
Aug 4, 2009·The Journal of Biological Chemistry·Mohammed Akli AyoubGrégoire Pierre Prévost
May 5, 2000·Fundamental & Clinical Pharmacology·L Daeffler, Y Landry
Jul 9, 2011·Pharmacological Reviews·Claudio CoddouStanko S Stojilkovic
Dec 24, 2002·Infection and Immunity·Kelly E WeatherbyWilliam P Lafuse
Jun 8, 2007·Microbiology and Molecular Biology Reviews : MMBR·Craig R Pigott, David J Ellar
Jan 3, 2013·The Journal of Clinical Investigation·Paolo E PorporatoAndrea Graziani
Jan 28, 2014·PloS One·Anna A PimenovaIna Tesseur
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·J StratmannC A Ryan
Jun 22, 2006·Proceedings of the National Academy of Sciences of the United States of America·Xuebin ZhangLee A Bulla
Apr 24, 2007·Journal of Insect Physiology·J Joe HullShogo Matsumoto
Jul 15, 2015·Scientific Reports·Michaela LiegertováZbyněk Kozmik
Oct 21, 2015·Frontiers in Pharmacology·Cédric Boularan, Céline Gales
Jan 25, 2002·Biophysical Journal·Nicole LehmannKarim Fahmy
Dec 21, 2005·Protein Expression and Purification·Lorenzo Di Cesare MannelliAlessandro Bartolini
Mar 8, 2003·Microbial Pathogenesis·D Scott Snyder, P L C Small
Mar 31, 2004·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·George M Carman, Michael C Kersting
Dec 29, 1998·The Journal of Biological Chemistry·M A BalboaE A Dennis
Sep 2, 2004·The Journal of Biological Chemistry·Jun TakasakiMasato Kobori
Sep 29, 2018·Nature Reviews. Drug Discovery·Adrian P Campbell, Alan V Smrcka
Aug 8, 2006·The Journal of Urology·Nicolas KalfaCharles Sultan
Apr 14, 2011·British Journal of Pharmacology·J M BrimsonS T Safrany
Jul 20, 2006·American Journal of Physiology. Renal Physiology·Clare M TurnerRobert J Unwin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics (ASM)

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.